Drugs / BMS-241027
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01492374 | Feb 2012 → Oct 2013 | Alzheimer disease | Bristol-Myers Squibb | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BMS-241027 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01492374 ↗ |
| Route | Intravenous | “following 9 weekly intravenous (IV) infusions of BMS-241027” NCT01492374 ↗ |